Patents by Inventor Robert J. Davies

Robert J. Davies has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7786107
    Abstract: The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.
    Type: Grant
    Filed: August 20, 2007
    Date of Patent: August 31, 2010
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Robert J. Davies, Jinwang Xu
  • Patent number: 7691853
    Abstract: This invention describes novel pyrazole compounds of formula IV: wherein Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; Rx and Ry are independently selected from T—R3, or taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-8 membered ring having 1-3 ring heteroatoms selected from oxygen, sulfur, or nitrogen; and R2, R2?, T, and R3 are as described in the specification. The compounds are useful as protein kinase inhibitors, especially as inhibitors of aurora-2 and GSK-3, for treating diseases such as cancer, diabetes and Alzheimer's disease.
    Type: Grant
    Filed: March 6, 2006
    Date of Patent: April 6, 2010
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: David Bebbington, Hayley Binch, Ronald Knegtel, Julian M. C. Golec, Sanjay Patel, Jean-Damien Charrier, David Kay, Robert J. Davies, Pan Li, Marion W. Wannamaker, Cornelia J. Forster, Albert C. Pierce
  • Publication number: 20100063021
    Abstract: The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.
    Type: Application
    Filed: August 20, 2007
    Publication date: March 11, 2010
    Inventors: Robert J. Davies, Jingwang Xu
  • Patent number: 7598245
    Abstract: The present invention relates to inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention, processes for preparing the compounds and methods of using the compositions in the treatment of various disorders.
    Type: Grant
    Filed: April 13, 2007
    Date of Patent: October 6, 2009
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Michael J. Arnost, Guy W. Bemis, Robert J. Davies, Cornelia J. Forster, Ronald Grey, Jr., Mark W. Ledeboer, Brian Ledford, Craig Marhefka, David Messersmith, Albert C. Pierce, Francesco G. Salituro, Jian Wang
  • Patent number: 7587207
    Abstract: A communications system comprises at least one beacon device capable of wireless message transmission and at least one portable device capable of receiving such a message transmission. The beacon is arranged to broadcast a series of inquiry messages each in the form of a plurality of predetermined data fields arranged according to a first communications protocol, such as Bluetooth. For the delivery of additional data via broadcast, and in particular data including location information, the beacon adds to each inquiry message prior to transmission an additional data field carrying broadcast data, with the portable device receiving the transmitted inquiry messages including the location data and reading the broadcast data from the additional data field.
    Type: Grant
    Filed: June 7, 2001
    Date of Patent: September 8, 2009
    Assignee: IPG Electronics 503 Limited
    Inventors: Robert J. Davies, Saul R. Dooley
  • Publication number: 20090099222
    Abstract: The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.
    Type: Application
    Filed: October 3, 2008
    Publication date: April 16, 2009
    Inventors: Robert J. Davies, Jinwang Xu, Rieko Arimoto
  • Publication number: 20090048226
    Abstract: The present invention relates to novel classes of compounds which are caspase inhibitors, in particular interleukin-1? converting enzyme (“ICE”) inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting caspase activity and consequently, may be advantageously used as agents against interleukin-1-(“IL-1”), apoptosis-, interferon-? inducing factor-(IGIF), or interferon-?-(“IFN-?”) mediated diseases, including inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, and degenerative diseases. This invention also relates to methods for inhibiting caspase activity and decreasing IGIF production and IFN-? production and methods for treating interleukin-1, apoptosis-, and interferon-?-mediated diseases using the compounds and compositions of this invention.
    Type: Application
    Filed: January 22, 2008
    Publication date: February 19, 2009
    Inventors: Marion W. Wannamaker, Guy W. Bemis, Paul S. Charifson, David J. Lauffer, Michael D. Mullican, Mark A. Murcko, Keith P. Wilson, James W. Janetka, Robert J. Davies, Anne-Laure Grillot, Zhan Shi, Cornelia J. Forster
  • Patent number: 7417029
    Abstract: This invention describes an ICE inhibitor prodrug (I) having good bioavailability Compound I is useful for treating IL-1 mediated diseases such as rheumatoid arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, inflammatory peritonitis, septic shock, pancreatitis, traumatic brain injury, organ transplant rejection, osteoarthritis, asthma, psoriasis, Alzheimer's disease, myocardial infarction, congestive heart failure, Huntington's disease, atherosclerosis, atopic dermatitis, leukemias and related disorders, myelodysplastic syndrome, uveitis or multiple myeloma.
    Type: Grant
    Filed: May 18, 2001
    Date of Patent: August 26, 2008
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Marion W Wannamaker, Robert J Davies
  • Publication number: 20080113958
    Abstract: The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.
    Type: Application
    Filed: August 20, 2007
    Publication date: May 15, 2008
    Inventors: Robert J. Davies, Jingwang Xu
  • Patent number: 7358273
    Abstract: The present invention relates to novel classes of compounds which are caspase inhibitors, in particular interleukin-1? converting enzyme (“ICE”) inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting caspase activity and consequently, may be advantageously used as agents against interleukin-1-(“IL-1”), apoptosis-, interferon-? inducing factor-(IGIF), or interferon-?-(“IFN-?”) mediated diseases, including inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, and degenerative diseases. This invention also relates to methods for inhibiting caspase activity and decreasing IGIF production and IFN-? production and methods for treating interleukin-1, apoptosis-, and interferon-?-mediated diseases using the compounds and compositions of this invention.
    Type: Grant
    Filed: December 6, 2002
    Date of Patent: April 15, 2008
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Marion W Wannamaker, Guy W Bemis, Paul S Charifson, David J Lauffer, Michael D Mullican, Mark A Murcko, Keith P Wilson, James W Janetka, Robert J Davies, Anne-Laure Grillot, Zhan Shi, Cornelia J Forster
  • Patent number: 7302244
    Abstract: An antenna diversity receiver comprises a zero-IF receiver connected to two antennas (102a, 102b) via switches (532, 534). Simultaneous measurement of signal qualities from both antennas is possible by routing signals from the first antenna (102a) via a first mixer (106) and channel filter (116) and routing signals from the second antenna (102b) via a second mixer (108) and channel filter (118). A diversity controller (536) compares the signal qualities received from the antennas (102a, 102b) during a data preamble to select a preferred antenna, then adjusts the switches (532, 534) to route the signals from the preferred antenna to both input mixers (106, 108). The amplifier (104a, 104b) connected to the deselected antenna may be switched off during data reception, thereby minimizing extra power consumption. Such an antenna diversity receiver enables effective antenna selection to be performed, even in systems such as Bluetooth where only a very short preamble is provided for receiver configuration.
    Type: Grant
    Filed: February 4, 2005
    Date of Patent: November 27, 2007
    Assignee: NXP B.V.
    Inventors: Adrian G. Spencer, Robert J. Davies
  • Patent number: 7279469
    Abstract: The present invention relates to inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
    Type: Grant
    Filed: November 17, 2003
    Date of Patent: October 9, 2007
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Albert C. Pierce, Michael Amost, Robert J. Davies, Cornelia J. Forster, Vincent Galullo, Ronald Grey, Jr., Mark Ledeboer, Shi-Kai Tian, Jinwang Xu, Hayley Binch, Brian Ledford, David Messersmith, Suganthi Nanthakumar, Andrew Jayaraj, Greg Henkel, Francesco G. Salituro, Jian Wang
  • Patent number: 7226920
    Abstract: The present invention relates to inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention, processes for preparing the compounds and methods of using the compositions in the treatment of various disorders.
    Type: Grant
    Filed: August 6, 2004
    Date of Patent: June 5, 2007
    Assignee: Vertex Pharmaceuticals Inc.
    Inventors: Michael J. Arnost, Guy W. Bemis, Robert J. Davies, Cornelia J. Forster, Ronald Grey, Jr., Mark W. Ledeboer, Brian Ledford, Craig Marhefka, David Messersmith, Albert C. Pierce, Francesco G. Salituro, Jian Wang
  • Patent number: 7197277
    Abstract: A communications system comprises at least one beacon device capable of wireless message transmission and at least one portable device capable of receiving such a message transmission. The beacon is arranged to broadcast a series of inquiry messages each in the form of a plurality of predetermined data fields (INQ) arranged according to a first communications protocol, such as Bluetooth. For the delivery of additional data via broadcast, the beacon adds to each inquiry message prior to transmission an additional data field (BCD) carrying audio data, with the portable device receiving the transmitted inquiry messages, reading the audio data from the additional data field, and reproducing the audio to a user.
    Type: Grant
    Filed: June 7, 2001
    Date of Patent: March 27, 2007
    Assignee: Koninklijke Philips Electronics N.V.
    Inventors: Robert J. Davies, Paul J. Rankin
  • Patent number: 7098330
    Abstract: This invention describes novel pyrazole compounds of formula III: wherein Ring D is a 5–7 membered monocyclic ring or 8–10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; Rx and Ry are taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5–8 membered carbocyclo ring; and R2 and R2? are as described in the specification. The compounds are useful as protein kinase inhibitors, especially as inhibitors of aurora-2 and GSK-3, for treating diseases such as cancer, diabetes and Alzheimer's disease.
    Type: Grant
    Filed: September 14, 2001
    Date of Patent: August 29, 2006
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: David Bebbington, Hayley Binch, Ronald Knegtel, Julian M. C. Golec, Sanjay Patel, Jean-Damien Charrier, David Kay, Robert J. Davies
  • Patent number: 6999519
    Abstract: A multicast radio data communication system comprising a master and a plurality of slave stations uses a retransmission protocol. Data is transmitted by the master station and received by the slave stations. Slave stations having the weakest radio link are designated primary stations, and all other slaves are designated secondary stations. Any slave station may transmit a negative acknowledgement but only the primary stations may transmit a positive acknowledgement. Positive acknowledgements are transmitted in separate time slots, but negative acknowledgements transmitted by the secondary stations overlap the positive acknowledgements transmitted by primary stations. These negative acknowledgements corrupt reception of the positive acknowledgement by the master station, thereby ensuring that the data is retransmitted.
    Type: Grant
    Filed: June 27, 2001
    Date of Patent: February 14, 2006
    Assignee: Koninklijke Philips Electronics N.V.
    Inventor: Robert J. Davies
  • Patent number: 6993049
    Abstract: A communications system comprises a primary station (100) and at least one secondary station (101). The primary station (100) is arranged to broadcast a series of inquiry messages, each in the form of a plurality of predetermined data fields arranged according to a first communications protocol such as Bluetooth. In addition the primary station (100) adds to some or all of the inquiry messages an additional data field for polling one or more secondary stations, which can respond to the poll if they have data for transmission. This system provides secondary stations (101) with a rapid response time without the need for a permanently active communication link.
    Type: Grant
    Filed: June 7, 2001
    Date of Patent: January 31, 2006
    Assignee: Koninklijke Philips Electronics N.V.
    Inventor: Robert J. Davies
  • Publication number: 20050261268
    Abstract: The present invention relates to inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention, processes for preparing the compounds and methods of using the compositions in the treatment of various disorders.
    Type: Application
    Filed: August 6, 2004
    Publication date: November 24, 2005
    Inventors: Michael J. Arnost, Guy W. Bemis, Robert J. Davies, Cornelia J. Forster, Ronald Grey, Mark W. Ledeboer, Brian Ledford, Craig Marhefka, David Messersmith, Albert C. Pierce, Francesco Salituro, Jian Wang
  • Patent number: 6928263
    Abstract: A communications system includes first and second beacon devices capable of wireless message transmission and at least one portable device capable of receiving such message transmissions. The first beacon is arrange to broadcast a series of inquiry messages according to a first communications protocol, such as Bluetooth. The portable device detects such inquiry messages and replies with an identifier for the portable device. The first beacon then transmits the received identifier to the second beacon, with the second beacon and portable device configured to perform a service interaction when triggered by the second beacon receiving the portable device identifier.
    Type: Grant
    Filed: June 4, 2001
    Date of Patent: August 9, 2005
    Assignee: Koninklijke Philips Electronics N.V.
    Inventors: Robert L. Blake, Robert J. Davies, Paul M. Fulton
  • Patent number: 6889900
    Abstract: A queue monitoring system is disclosed. A detection system (10) provides at least one coverage zone (15) covering at least a part of a queuing area (30). A handset (12) is issued to a user, the detection system (10) being arranged to detect the handset (12) when it is within the coverage zone (15) and to record the user of the handset as being in the queue. Queue load is subsequently used to provide recommended itineraries to visitors via the handsets (12).
    Type: Grant
    Filed: July 1, 2002
    Date of Patent: May 10, 2005
    Assignee: Koninklijke Philips Electronics N.V.
    Inventors: Robert J. Davies, Paul M. Fulton